2026 Q1 -tulosraportti
37 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,13%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 1 920 | - | - | ||
| 2 000 | - | - | ||
| 695 | - | - | ||
| 550 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
1 t sitten1 t sittenToday will be the biggest gain of the year +7%. Not investment advice, just entertainment. Do your own research.
·5 t sittenIt seems to be starting to pick up now for Novo. They might not have the most extreme injections in terms of efficacy, but they are right behind and with a significantly better tolerance profile and cardiovascular benefits. In addition, the Wegovy pill is starting to gain a much larger first-mover effect in Europe. UK first, then EU with probably priority on Germany and France. The price of the pill is low enough that Europeans who want it can, in many cases, also afford it (without reimbursement) Closest pill competitor Foundayo is already struggling big time in the USA. Analysts from the same country are still holding firmly to Foundayo's user-friendliness, but strangely enough, at the same time avoid mentioning prevention and friction for up to 30% of weight loss pill customers1 t sitten1 t sittenYes, I officially announced lift off yesterday. Today, it will erupt +6%.
·7 t sittenUSA is really stepping on the gas. But the best products always win. Doctors do not give lillypills, as there are far far too many side effects in simple and in complex patient cases where they take other medicine such as e.g. birth control pills: Novo Nordisk has been hit by hackers Novo Nordisk has identified what the company describes as an IT security incident, involving unauthorized access to a limited number of internal IT systems. The core business is not affected and continues to operate normally.
·6 t sittenI definitely also believe that Novo will rise. But do the best products really always win? Has there never been a company that had a better product that didn't succeed?
·9 t sitten285,5 in USA pt.
·8 t sittenTrump cancels an attack that was never planned. And says that an agreement has been reached with Iran (again a lie) but the market reacts to his lies. Anyone can surely figure out that one would not announce an attack.·7 t sittenFirst and foremost, he said nothing about the island, but just that he would attack Iran hard again, and the market reacted to that, as it was not unlikely after they have done so the last couple of days. I don't think the market expects a deal, as it is an obvious lie again
·10 t sittenNovo Nordisk's Wegovy pill approved in the UK Novo Nordisk has received approval for its Wegovy pill in the UK. The pharmaceutical giant announced this in a stock exchange release on Thursday, just after market close. The pill has been approved by the British medicines agency, making it the first weight loss pill on the British market. "This is a landmark approval, which makes the UK the first country in Europe to approve the Wegovy® pill," says Emil Kongshøj Larsen, Corporate Vice President for International Operations at Novo Nordisk, in the announcement. The UK is the third country where Novo Nordisk has received permission to sell the Wegovy pill. The pill has been available in the USA since the New Year, but it was also recently approved in the United Arab Emirates.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
37 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,13%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 1 t sitten1 t sittenToday will be the biggest gain of the year +7%. Not investment advice, just entertainment. Do your own research.
- ·5 t sittenIt seems to be starting to pick up now for Novo. They might not have the most extreme injections in terms of efficacy, but they are right behind and with a significantly better tolerance profile and cardiovascular benefits. In addition, the Wegovy pill is starting to gain a much larger first-mover effect in Europe. UK first, then EU with probably priority on Germany and France. The price of the pill is low enough that Europeans who want it can, in many cases, also afford it (without reimbursement) Closest pill competitor Foundayo is already struggling big time in the USA. Analysts from the same country are still holding firmly to Foundayo's user-friendliness, but strangely enough, at the same time avoid mentioning prevention and friction for up to 30% of weight loss pill customers1 t sitten1 t sittenYes, I officially announced lift off yesterday. Today, it will erupt +6%.
- ·7 t sittenUSA is really stepping on the gas. But the best products always win. Doctors do not give lillypills, as there are far far too many side effects in simple and in complex patient cases where they take other medicine such as e.g. birth control pills: Novo Nordisk has been hit by hackers Novo Nordisk has identified what the company describes as an IT security incident, involving unauthorized access to a limited number of internal IT systems. The core business is not affected and continues to operate normally.·6 t sittenI definitely also believe that Novo will rise. But do the best products really always win? Has there never been a company that had a better product that didn't succeed?
- ·9 t sitten285,5 in USA pt.·8 t sittenTrump cancels an attack that was never planned. And says that an agreement has been reached with Iran (again a lie) but the market reacts to his lies. Anyone can surely figure out that one would not announce an attack.·7 t sittenFirst and foremost, he said nothing about the island, but just that he would attack Iran hard again, and the market reacted to that, as it was not unlikely after they have done so the last couple of days. I don't think the market expects a deal, as it is an obvious lie again
- ·10 t sittenNovo Nordisk's Wegovy pill approved in the UK Novo Nordisk has received approval for its Wegovy pill in the UK. The pharmaceutical giant announced this in a stock exchange release on Thursday, just after market close. The pill has been approved by the British medicines agency, making it the first weight loss pill on the British market. "This is a landmark approval, which makes the UK the first country in Europe to approve the Wegovy® pill," says Emil Kongshøj Larsen, Corporate Vice President for International Operations at Novo Nordisk, in the announcement. The UK is the third country where Novo Nordisk has received permission to sell the Wegovy pill. The pill has been available in the USA since the New Year, but it was also recently approved in the United Arab Emirates.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 1 920 | - | - | ||
| 2 000 | - | - | ||
| 695 | - | - | ||
| 550 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
37 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,13%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 1 t sitten1 t sittenToday will be the biggest gain of the year +7%. Not investment advice, just entertainment. Do your own research.
- ·5 t sittenIt seems to be starting to pick up now for Novo. They might not have the most extreme injections in terms of efficacy, but they are right behind and with a significantly better tolerance profile and cardiovascular benefits. In addition, the Wegovy pill is starting to gain a much larger first-mover effect in Europe. UK first, then EU with probably priority on Germany and France. The price of the pill is low enough that Europeans who want it can, in many cases, also afford it (without reimbursement) Closest pill competitor Foundayo is already struggling big time in the USA. Analysts from the same country are still holding firmly to Foundayo's user-friendliness, but strangely enough, at the same time avoid mentioning prevention and friction for up to 30% of weight loss pill customers1 t sitten1 t sittenYes, I officially announced lift off yesterday. Today, it will erupt +6%.
- ·7 t sittenUSA is really stepping on the gas. But the best products always win. Doctors do not give lillypills, as there are far far too many side effects in simple and in complex patient cases where they take other medicine such as e.g. birth control pills: Novo Nordisk has been hit by hackers Novo Nordisk has identified what the company describes as an IT security incident, involving unauthorized access to a limited number of internal IT systems. The core business is not affected and continues to operate normally.·6 t sittenI definitely also believe that Novo will rise. But do the best products really always win? Has there never been a company that had a better product that didn't succeed?
- ·9 t sitten285,5 in USA pt.·8 t sittenTrump cancels an attack that was never planned. And says that an agreement has been reached with Iran (again a lie) but the market reacts to his lies. Anyone can surely figure out that one would not announce an attack.·7 t sittenFirst and foremost, he said nothing about the island, but just that he would attack Iran hard again, and the market reacted to that, as it was not unlikely after they have done so the last couple of days. I don't think the market expects a deal, as it is an obvious lie again
- ·10 t sittenNovo Nordisk's Wegovy pill approved in the UK Novo Nordisk has received approval for its Wegovy pill in the UK. The pharmaceutical giant announced this in a stock exchange release on Thursday, just after market close. The pill has been approved by the British medicines agency, making it the first weight loss pill on the British market. "This is a landmark approval, which makes the UK the first country in Europe to approve the Wegovy® pill," says Emil Kongshøj Larsen, Corporate Vice President for International Operations at Novo Nordisk, in the announcement. The UK is the third country where Novo Nordisk has received permission to sell the Wegovy pill. The pill has been available in the USA since the New Year, but it was also recently approved in the United Arab Emirates.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 1 920 | - | - | ||
| 2 000 | - | - | ||
| 695 | - | - | ||
| 550 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt